# Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

> **NCT03850483** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 344 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** PF-06700841
- **DRUG:** Vehicle (Placebo)

## Key facts

- **NCT ID:** NCT03850483
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-08
- **Primary completion:** 2021-04-20
- **Final completion:** 2021-04-20
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2022-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850483, "Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03850483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*